CoChat
Sign Up
Cited by 2,063CAR-T cell therapy researchAcute Lymphoblastic Leukemia researchImmunotherapy and Immune Responses

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Open access
Brentjens, Renier J., Davila, Marco L., Riviere, Isabelle, Park, Jae, Wang, Xiuyan, Cowell, Lindsay G., Bartido, Shirley, Stefanski, Jolanta +17 more·2013·Science Translational Medicine
DOI 10.1126/scitranslmed.3005930PMC PMC3742551
Open this paper in CoChat — free account

Abstract

Five adults with chemotherapy-refractory B-ALL were induced into molecular remissions after treatment with CD19 CAR-targeted T cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3005930

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals.

    “All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”

    From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [10]

    The Introduction identifies the study’s CD28-containing CAR as second-generation, and the Discussion describes a second-generation CAR containing 4-1BB. Neither section establishes that all approved CAR T-cell products use one of these designs; the paper discusses clinical studies rather than approved products. Page numbers are not available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Most clinical protocols and all commercially approved therapies have relied on viral vectors to deliver CAR transgenes into T cells.

    “Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”

    From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [10]

    Materials and Methods (Generation of 19-28z CAR modified T cells; page unavailable) says the trial's T cells were transduced with gammaretroviral 19-28z supernatant, supporting this protocol as an example of viral-vector delivery. The paper does not establish that most clinical protocols or all commercially approved CAR-T therapies use viral vectors. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing.

    “First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”

    From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [10]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 25

  1. [1]Fielding AK Richards SM Chopra R Lazarus HM Litzow MR Buck G Durrant IJ Luger SM Marks DI Franklin IM McMillan AK Tallman MS Rowe JM Goldstone AH Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study Blood 2007 109 944 17032921
  2. [2]Gokbuget N Stanze D Beck J Diedrich H Horst HA Huttmann A Kobbe G Kreuzer KA Leimer L Reichle A Schaich M Schwartz S Serve H Starck M Stelljes M Stuhlmann R Viardot A Wendelin K Freund M Hoelzer D Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation Blood 2012 120 2032 22493293
  3. [3]Bassan R Spinelli O Oldani E Intermesoli T Tosi M Peruta B Rossi G Borlenghi E Pogliani EM Terruzzi E Fabris P Cassibba V Lambertenghi-Deliliers G Cortelezzi A Bosi A Gianfaldoni G Ciceri F Bernardi M Gallamini A Mattei D Di Bona E Romani C Scattolin AM Barbui T Rambaldi A Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood 2009 113 4153 19141862
  4. [4]Brentjens RJ Latouche JB Santos E Marti F Gong MC Lyddane C King PD Larson S Weiss M Riviere I Sadelain M Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat Med 2003 9 279 12579196
  5. [5]Cooper LJ Topp MS Serrano LM Gonzalez S Chang WC Naranjo A Wright C Popplewell L Raubitschek A Forman SJ Jensen MC T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect Blood 2003 101 1637 12393484
  6. [6]Kochenderfer JN Yu Z Frasheri D Restifo NP Rosenberg SA Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells Blood 2010 116 3875 20631379 PMC2981541
  7. [7]Milone MC Fish JD Carpenito C Carroll RG Binder GK Teachey D Samanta M Lakhal M Gloss B Danet-Desnoyers G Campana D Riley JL Grupp SA June CH Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Molecular therapy: the journal of the American Society of Gene Therapy 2009 17 1453 19384291 PMC2805264
  8. [8]Brentjens RJ Riviere I Park JH Davila ML Wang X Stefanski J Taylor C Yeh R Bartido S Borquez-Ojeda O Olszewska M Bernal Y Pegram H Przybylowski M Hollyman D Usachenko Y Pirraglia D Hosey J Santos E Halton E Maslak P Scheinberg D Jurcic J Heaney M Heller G Frattini M Sadelain M Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 2011 118 4817 21849486 PMC3208293
  9. [9]Kalos M Levine BL Porter DL Katz S Grupp SA Bagg A June CH T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 2011 3 95ra73 PMC3393096 21832238
  10. [10]Kochenderfer JN Dudley ME Feldman SA Wilson WH Spaner DE Maric I Stetler-Stevenson M Phan GQ Hughes MS Sherry RM Yang JC Kammula US Devillier L Carpenter R Nathan DA Morgan RA Laurencot C Rosenberg SA B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 2011 PMC3327450 22160384
  11. [11]Kochenderfer JN Wilson WH Janik JE Dudley ME Stetler-Stevenson M Feldman SA Maric I Raffeld M Nathan DA Lanier BJ Morgan RA Rosenberg SA Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 2010 116 4099 20668228 PMC2993617
  12. [12]Porter DL Levine BL Kalos M Bagg A June CH Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 2011 365 725 21830940 PMC3387277
  13. [13]Hollyman D Stefanski J Przybylowski M Bartido S Borquez-Ojeda O Taylor C Yeh R Capacio V Olszewska M Hosey J Sadelain M Brentjens RJ Riviere I Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy J Immunother 2009 32 169 19238016 PMC2683970
  14. [14]Jensen MC Popplewell L Cooper LJ DiGiusto D Kalos M Ostberg JR Forman SJ Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans Biol Blood Marrow Transplant 2010 16 1245 20304086 PMC3383803
  15. [15]Savoldo B Ramos CA Liu E Mims MP Keating MJ Carrum G Kamble RT Bollard CM Gee AP Mei Z Liu H Grilley B Rooney CM Heslop HE Brenner MK Dotti G CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients J Clin Invest 2011 121 1822 21540550 PMC3083795
  16. [16]Davila M Brentjens R Wang X Riviere I Sadelain M How do CARs work?: Early insights from recent clinical studies targeting CD19 OncoImmunology 2012 1 1577 23264903 PMC3525612
  17. [17]Imai C Mihara K Andreansky M Nicholson IC Pui CH Geiger TL Campana D Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 2004 18 676 14961035
  18. [18]Brentjens RJ Santos E Nikhamin Y Yeh R Matsushita M La Perle K Quintas-Cardama A Larson SM Sadelain M Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts Clin Cancer Res 2007 13 5426 17855649
  19. [19]Zhong XS Matsushita M Plotkin J Riviere I Sadelain M Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication Molecular therapy: the journal of the American Society of Gene Therapy 2010 18 413 19773745 PMC2839303
  20. [20]Goldberg JD Linker A Kuk D Ratan R Jurcic J Barker JN Castro-Malaspina H Giralt S Hsu K Jakubowski AA Jenq R Koehne G Papadopoulos EB van den Brink MR Young JW Boulad F Kernan NA O’Reilly RJ Prockop SE Yahalom J Heller G Perales MA T Cell-Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft- versus-Host Disease Biol Blood Marrow Transplant 2013 19 208 22982534 PMC3963704
  21. [21]Fielding AK Rowe JM Richards SM Buck G Moorman AV Durrant IJ Marks DI McMillan AK Litzow MR Lazarus HM Foroni L Dewald G Franklin IM Luger SM Paietta E Wiernik PH Tallman MS Goldstone AH Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993 Blood 2009 113 4489 19244158 PMC4188540
  22. [22]Kantarjian HM O’Brien S Smith TL Cortes J Giles FJ Beran M Pierce S Huh Y Andreeff M Koller C Ha CS Keating MJ Murphy S Freireich EJ Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2000 18 547 10653870
  23. [23]Kantarjian H Thomas D Jorgensen J Jabbour E Kebriaei P Rytting M York S Ravandi F Kwari M Faderl S Rios MB Cortes J Fayad L Tarnai R Wang SA Champlin R Advani A O’Brien S Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study Lancet Oncol 2012 13 403 22357140
  24. [24]Rowe JM Buck G Burnett AK Chopra R Wiernik PH Richards SM Lazarus HM Franklin IM Litzow MR Ciobanu N Prentice HG Durrant J Tallman MS Goldstone AH Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993 Blood 2005 106 3760 16105981
  25. [25]Steinherz PG Redner A Steinherz L Meyers P Tan C Heller G Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol Cancer 1993 72 3120 8221579

Cited by

Sorted by citations

Authors
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, I. V., Hedvat, C., Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., Maslak, P., Frattini, M., & Sadelain, M.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
  • The University of Texas Southwestern Medical Center (US)
  • Cell Therapy and Cell Engineering Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Corresponding author
  • Brentjens, Renier J.
  • Davila, Marco L.
  • Sadelain, Michel
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2013-03-20
Volume
5
Issue
177
Pages
177ra38-177ra38
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.3005930
PMC
PMC3742551
OpenAlex
W2130338247
Cited by
2,063
References
0
Citations by year
2026: 38 · 2025: 89 · 2024: 110 · 2023: 126 · 2022: 133 · 2021: 157 · 2020: 195 · 2019: 207 · 2018: 221 · 2017: 191 · 2016: 188 · 2015: 172 · 2014: 134 · 2013: 93 · 2012: 4
FWCI
104.85
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (K08CA148821, P30CA008748, P30CA076292, T32CA009207, R25CA020449)
  • National Institute of Allergy and Infectious Diseases (R01AI097403)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CD19 CAR T cells, relapsed B-cell acute lymphoblastic leukemia, minimal residual disease, molecular remission, cytokine release syndrome, autologous T cell therapy, refractory leukemia
MeSH terms
Adult, Aged, Cells, Cultured, Female, Humans, Immunotherapy, Male, Middle Aged, T-Lymphocytes, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review